Novartis, a pharmaceutical business, reported that its net income for the first nine months of 2022 decreased by 29% from the same period last year to $5.489 billion. In comparison to $3.44 a year earlier, Novartis' diluted earnings per share for the three quarters was $2.5. Revenue decreased 1%...